2022-RA-1517-ESGO Wroclaw comprehensive cancer centre 100 months experience in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) in patients with peritoneal carcinomatosis – indications and complications of the procedure
{"title":"2022-RA-1517-ESGO Wroclaw comprehensive cancer centre 100 months experience in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) in patients with peritoneal carcinomatosis – indications and complications of the procedure","authors":"K. Szewczyk, M. Jedryka, M. Bębenek","doi":"10.1136/ijgc-2022-esgo.734","DOIUrl":null,"url":null,"abstract":"impact 5-year DFS (p=0.552). At univari-ate analysis the only significant variable affecting DFS was the performance of lymphadenectomy (HR:0.388; 95% CI:0.174 – 0.866;p=0.021). Abstract 2022-RA-1515-ESGO Figure 1 Conclusion In a retrospective multicenter series of low-grade endometrioid ovarian cancers apparently confined to the ovary, lymphadenectomy appeared to be associated with improved DFS. Adjuvant chemotherapy did not impact DFS. Nevertheless, the present results derive from a retrospective uncontrolled study, in which the indication for or against lym-phadenectomy/adjuvant chemotherapy was not prospectively defined, causing potential significant selection bias.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ovarian cancer and other gynecologic malignancies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-esgo.734","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
impact 5-year DFS (p=0.552). At univari-ate analysis the only significant variable affecting DFS was the performance of lymphadenectomy (HR:0.388; 95% CI:0.174 – 0.866;p=0.021). Abstract 2022-RA-1515-ESGO Figure 1 Conclusion In a retrospective multicenter series of low-grade endometrioid ovarian cancers apparently confined to the ovary, lymphadenectomy appeared to be associated with improved DFS. Adjuvant chemotherapy did not impact DFS. Nevertheless, the present results derive from a retrospective uncontrolled study, in which the indication for or against lym-phadenectomy/adjuvant chemotherapy was not prospectively defined, causing potential significant selection bias.